| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | SEAK THERAPEUTICS, LLC | 3 N DUNLAP ST STE C303 | MEMPHIS | TN | 38103-2802 | SHELBY | USA | R41NS135658 | Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment | 000 | 1 | NIH | 3/31/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2020 | SEAK THERAPEUTICS, LLC | 3 N DUNLAP ST STE C303 | MEMPHIS | TN | 38103-2802 | SHELBY | USA | R43CA257324 | Feasibility study of developing SEAK-114 for the treatment of pediatric cancers | 000 | 1 | NIH | 10/13/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $429,932 ) |
| | 2023 | 2023 | SEAK THERAPEUTICS LLC | 3 N DUNLAP ST | MEMPHIS | TN | 38103-2802 | SHELBY | USA | R41NS135658 | Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment | 000 | 1 | NIH | 9/20/2023 | $429,932 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | SEAK THERAPEUTICS, LLC | 3 N DUNLAP ST STE C303 | MEMPHIS | TN | 38103-2802 | SHELBY | USA | R43CA257324 | Feasibility study of developing SEAK-114 for the treatment of pediatric cancers | 000 | 1 | NIH | 8/30/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | SEAK THERAPEUTICS, LLC | 20 DUDLEY ST STE 900 | MEMPHIS | TN | 38103-4904 | SHELBY | USA | R43CA257324 | Feasibility study of developing SEAK-114 for the treatment of pediatric cancers | 000 | 1 | NIH | 1/7/2021 | $0 |
| | 2021 | 2019 | SEAK THERAPEUTICS, LLC | 3 N DUNLAP ST STE C303 | MEMPHIS | TN | 38103-2802 | SHELBY | USA | R43CA246788 | Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers | 000 | 1 | NIH | 3/19/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $454,964 ) |
| | 2020 | 2020 | SEAK THERAPEUTICS, LLC | 20 DUDLEY ST STE 900 | MEMPHIS | TN | 38103-4904 | SHELBY | USA | R43CA246788 | Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers | 000 | 1 | NIH | 8/12/2020 | $55,000 |
| | 2020 | 2020 | SEAK THERAPEUTICS, LLC | 20 DUDLEY ST STE 900 | MEMPHIS | TN | 38103-4904 | SHELBY | USA | R43CA257324 | Feasibility study of developing SEAK-114 for the treatment of pediatric cancers | 000 | 1 | NIH | 9/17/2020 | $399,964 |
|
| Issue Date FY: 2019 ( Subtotal = $299,823 ) |
| | 2019 | 2019 | SEAK THERAPEUTICS, LLC | 20 DUDLEY ST STE 900 | MEMPHIS | TN | 38103-4904 | SHELBY | USA | R43CA246788 | Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers | 000 | 1 | NIH | 9/12/2019 | $299,823 |
|
|
